Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
mRNA-4359 advances to phase 2 following encouraging results in checkpoint inhibitor-resistant Melanoma
First patients enrolled in Phase I trial with KQB548, an investigational KRAS inhibitor designed to treat KRAS G12D-mutated tumors
Pioneering innovation aims to transform anticoagulant therapy and improve patient outcomes
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Subscribe To Our Newsletter & Stay Updated
